Trial Profile
Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI in Patients With STEMI.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Oct 2011
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Myocardial reperfusion injury
- Focus Therapeutic Use
- Acronyms POSTCON-II
- 14 Sep 2011 Results published in the European Heart Journal.
- 22 Dec 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 11 Feb 2009 New trial record